The inaugural ALGS Open is set to begin at the Ernest N. Morial Convention Center from May 1-4, 2025, marking what is ...

Apex Legends will hold one of its biggest events to date in New Orleans this May, as the ALGS Open will feature 160 Pro ...

Equities research analysts at HC Wainwright reduced their Q1 2025 earnings per share estimates for shares of Aligos Therapeutics in a report issued on Tuesday, March 11th. HC Wainwright analyst E.

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best ...

Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral ...

Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) is expected to be releasing its earnings data before the market opens on ...

With all three Year 5 LANs condensing to four-day events, the ALGS Open is going to have four matches running concurrently, with one on the main stage and the other three on the floor. With so ...

R&D expenses for the year ended December 31, 2024 were $70.3 million, compared with $73.0 million for the same period of 2023. Total R&D employee-related costs reduced by $4.2 million which was ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

SOUTH SAN FRANCISCO, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biotechnology ...

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in in developing therapeutics for chronic liver diseases and viral infections. The firm is focused on the ...